ERBB2 and breast cancer: In patients treated with NAC, the pooled analysis showed that high TIL levels could predict pathological response in all breast cancer subtypes and were associated with longer DFS in the TNBC and HER2+ but not the luminal‐HER2− subtype.3, 8